Submitted by amarin on Wed, 04/11/2018 - 19:44 Home ID Reference 15201 News title Amarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on REDUCE-IT Cardiovascular Outcomes Study Progress and Vascepa® Promotion Initiatives
